Groundbreaking cancer drug enters first human trials
NCT ID NCT06403436
Summary
This is the first human study testing a new cancer drug called TT125-802 in people with advanced solid tumors that have stopped responding to standard treatments. The main goal is to check if the drug is safe and well-tolerated, while also looking for early signs that it might help shrink tumors. The study will enroll 50 adults with various advanced cancers including certain lung cancers to determine the right dose for future research.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Centre Hospitalier Universitaire Vaudois
RECRUITINGLausanne, 1890, Switzerland
Contact
-
Ente Ospedaliero Cantonale
RECRUITINGBellinzona, 6500, Switzerland
Contact
-
NEXT Oncology Barcelona
RECRUITINGBarcelona, 08023, Spain
Contact
-
NEXT Oncology Madrid
RECRUITINGMadrid, 28223, Spain
Contact
-
NEXT Oncology Virginia
RECRUITINGFairfax, Virginia, 22031, United States
Contact
-
Sarah Cannon Research Institute Oncology Partners
RECRUITINGNashville, Tennessee, 37203, United States
Contact
-
Vall d'Hebron Institute of Oncology
RECRUITINGBarcelona, 08035, Spain
Contact
Conditions
Explore the condition pages connected to this study.